Anavex Life Sciences (AVXL) vs Eloxx Pharmaceuticals (ELOX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Anavex Life Sciences is the larger company by market cap ($54.8 million vs $43.7 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVXL | ELOX |
|---|---|---|
| Share price | $0.5915 | $10.69 |
| Market cap | $54.83M | $43.69M |
| 1-day change | -11.39% | -1.75% |
| YTD return | -83.38% | — |
| 1-year return | -81.86% | — |
| 5-year return | -96.96% | — |
| P/E ratio (TTM) | — | 5.63 |
| EPS (TTM) | $-0.14 | $1.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-46.38M | $-6.00M |
| 52-week high | $5.36 | $23.40 |
| 52-week low | $0.59 | $8.20 |
| Distance from 52-week high | -88.96% | -54.32% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +257.81% |
| Average volume | 1.15M | 28.48K |
| Shares outstanding | 92.70M | 4.09M |
| Employees | 34 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
AVXL vs ELOX FAQ
Which is bigger, Anavex Life Sciences or Eloxx Pharmaceuticals?
Anavex Life Sciences (AVXL) is larger, with a market capitalization of $54.83M compared with $43.69M for Eloxx Pharmaceuticals (ELOX).
Are Anavex Life Sciences and Eloxx Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.